Differential risk of severe infection in febrile neutropenia among children with blood cancer or solid tumor

被引:14
作者
Delebarre, Mathilde [1 ,2 ,3 ]
Dessein, Rodrigue [1 ,4 ]
Lagree, Marion [3 ]
Mazingue, Francoise [5 ]
Sudour-Bonnange, Helene [6 ]
Martinot, Alain [1 ,2 ,3 ]
Dubos, Francois [1 ,2 ,3 ]
机构
[1] Univ Lille, CHU Lille, 2 Ave Oscar Lambret, F-59000 Lille, France
[2] Publ Hlth Epidemiol & Qual Care, EA 2694, F-59000 Lille, France
[3] CHU Lille, Pediat Emergency Unit & Infect Dis, F-59000 Lille, France
[4] CHU Lille, Microbiol Unit, Pathol Biol Ctr, F-59000 Lille, France
[5] CHU Lille, Pediat Hematol Unit, F-59000 Lille, France
[6] Oscar Lambret Canc Ctr, Pediat Oncol Unit, F-59000 Lille, France
关键词
Children; Febrile neutropenia; Cancer; Risk of infection; Prediction; CHEMOTHERAPY-INDUCED NEUTROPENIA; PEDIATRIC HEMATOLOGY; BACTERIAL-INFECTION; ONCOLOGY PATIENTS; FEVER; MANAGEMENT; BACTEREMIA; OUTCOMES; HOSPITALIZATION; MALIGNANCIES;
D O I
10.1016/j.jinf.2019.06.008
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To describe and analyze the differences between infections in children with febrile neutropenia (FN) treated for solid tumor or blood cancer. Methods: A prospective study included all episodes of FN in children from April 2007 to April 2016 in 2-pediatric cancer centers in France. Medical history, clinical and laboratory data available at admission and final microbiological data were collected. The proportion of FN, severe infection, categories of microorganisms and outcomes were compared between the two groups. The presumed gateway of the infection was a posteriori considered and evaluated. Results: We analyzed 1197 FN episodes (mean age: 8 years). 66% of the FN episodes occurred in children with blood cancer. Severe infections were identified in 23.4% of episodes overall. The rate of severe infection (28.4% vs. 10.4%), types of microorganisms and the need for a management in intensive care unit (2.6% vs. 0.5%) was significantly different between children with blood cancer and solid tumor. Digestive or respiratory presumed gateway of the infections was less frequent for patients with solid tumor. Conclusion: Given these important microbiological and clinical differences, it may be appropriate to consider differently the risk of severe infection in these two populations and therefore the management of FN. (C) 2019 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:95 / 100
页数:6
相关论文
共 50 条
  • [31] Predicting bacterial infections among pediatric cancer patients with febrile neutropenia: External validation of the PICNICC model
    Ojha, Rohit P.
    Asdahl, Peter H.
    Steyerberg, EwoutW.
    Schroeder, Henrik
    PEDIATRIC BLOOD & CANCER, 2018, 65 (04)
  • [32] Through Their Eyes: Parental Perceptions on Hospital Admissions for Febrile Neutropenia in Children With Cancer
    Anderson, Katrina J.
    Bradford, Natalie K.
    Clark, Julia E.
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2018, 35 (05) : 342 - 352
  • [33] Cytokine and chemokine profiles in episodes of persistent high-risk febrile neutropenia in children with cancer
    Tapia, Lorena, I
    Olivares, Mauricio
    Torres, Juan P.
    De la Maza, Veronica
    Valenzuela, Romina
    Contardo, Veronica
    Tordecilla, Juan
    Alvarez, Ana M.
    Varas, Monica
    Zubieta, Marcela
    Salgado, Carmen
    Venegas, Marcela
    Gutierrez, Valentina
    Claverie, Ximena
    Villarroel, Milena
    Santolaya, Maria E.
    CYTOKINE, 2021, 148
  • [34] Multisite External Validation of a Risk Prediction Model for the Diagnosis of Blood Stream Infections in Febrile Pediatric Oncology Patients Without Severe Neutropenia
    Esbenshade, Adam J.
    Zhao, Zhiguo
    Aftandilian, Catherine
    Saab, Raya
    Wattier, Rachel L.
    Beauchemin, Melissa
    Miller, Tamara P.
    Wilkes, Jennifer J.
    Kelly, Michael J.
    Fernbach, Alison
    Jeng, Michael
    Schwartz, Cindy L.
    Dvorak, Christopher C.
    Shyr, Yu
    Moons, Karl G. M.
    Sulis, Maria-Luisa
    Friedman, Debra L.
    CANCER, 2017, 123 (19) : 3781 - 3790
  • [35] Microorganisms isolated from blood cultures in children with cancer and high-risk febrile neutropenia from five hospitals in Santiago, Chile, 2012-2015
    Eliana Maldonado, M.
    Acuna, Mirta
    Alvarez, Ana M.
    Aviles, Carmen L.
    de la Maza, Veronica
    Salgado, Carmen
    Tordecilla, Juan
    Varas, Monica
    Venegas, Marcela
    Villarroel, Milena
    Zubieta, Marcela
    Elena Santolaya, M.
    REVISTA CHILENA DE INFECTOLOGIA, 2018, 35 (02): : 140 - 146
  • [36] Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country
    Joudeh, Nagham
    Sawafta, Elana
    Taha, Adham Abu
    Allah, Majd Hamed
    Amer, Riad
    Odeh, Razan Y. Y.
    Salameh, Husam
    Sabateen, Ali
    Aiesh, Banan M.
    Zyoud, Sa'ed H.
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [37] Addressing the barriers to optimal management of febrile neutropenia in children with cancer
    Anderson, Katrina
    Bradford, Natalie
    Edwards, Rachel
    Nicholson, Jessica
    Lockwood, Liane
    Clark, Julia
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2020, 45
  • [38] Timing of Pegfilgrastim: Association with Febrile Neutropenia in a Pediatric Solid and CNS Tumor Population
    Schlenker, Laura
    Manworren, Renee C. B.
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2021, 38 (06) : 375 - 384
  • [39] Antibiotic treatment in children with High Risk Febrile Neutropenia
    Munoz B, Eliana
    Cristobal Ossa A, Juan
    Villarroel C, Milena
    Santolaya D P, Maria Elena
    REVISTA CHILENA DE PEDIATRIA-CHILE, 2008, 79 (04): : 381 - 387
  • [40] FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis
    Todaka, Akiko
    Sasaki, Mitsuhito
    Ueno, Hideki
    Goto, Takuma
    Murohisa, Gou
    Mizuno, Nobumasa
    Ozaka, Masato
    Kobayashi, Satoshi
    Uesugi, Kazuhiro
    Kobayashi, Noritoshi
    Hayashi, Hideyuki
    Sudo, Kentaro
    Okano, Naohiro
    Horita, Yosuke
    Kamei, Keiko
    Nanami, Shoko
    Boku, Narikazu
    ANTICANCER RESEARCH, 2023, 43 (09) : 4115 - 4123